KUBACKOVA, Katerina, Bohuslav MELICHAR, Zbyněk BORTLÍČEK, Tomáš PAVLÍK, Alexandr POPRACH, Marek SVOBODA, Radek LAKOMY, Rostislav VYZULA, Igor KISS, Ladislav DUŠEK, Jana PRAUSOVA a Tomas BUCHLER. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study. Targeted Oncology, Dordrecht: Springer, 2015, roč. 10, č. 4, s. 557-563. ISSN 1776-2596. doi:10.1007/s11523-015-0366-9.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study
Autoři KUBACKOVA, Katerina (203 Česká republika), Bohuslav MELICHAR (203 Česká republika), Zbyněk BORTLÍČEK (203 Česká republika, garant, domácí), Tomáš PAVLÍK (203 Česká republika, domácí), Alexandr POPRACH (203 Česká republika), Marek SVOBODA (203 Česká republika), Radek LAKOMY (203 Česká republika), Rostislav VYZULA (203 Česká republika), Igor KISS (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí), Jana PRAUSOVA (203 Česká republika) a Tomas BUCHLER (203 Česká republika).
Vydání Targeted Oncology, Dordrecht, Springer, 2015, 1776-2596.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Nizozemsko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 3.197
Kód RIV RIV/00216224:14110/15:00085865
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1007/s11523-015-0366-9
UT WoS 000365770300010
Klíčová slova anglicky CELL CARCINOMA; TARGETED THERAPY; SURVIVAL; VALIDATION; PROGRESSION; CYTOKINES; CRITERIA; DATABASE
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 12. 1. 2016 15:59.
Anotace
The study aimed to compare two prognostic models in terms of progression-free survival (PFS), median overall survival (OS), and 1-year survival in patients treated first-line with sunitinib for metastatic renal cell carcinoma (mRCC). Data from patients who met prognostic model criteria for recording of baseline parameters and outcomes in the Czech Patient Registry RENal Information System (RENIS) were included in the retrospective analysis (n = 495). Performance of the modified Memorial Sloan Kettering Cancer Center (MSKCC) model and International Database Consortium (IDC) model was compared. PFS and OS were estimated using the Kaplan-Meier method. The statistical significance of differences in Kaplan-Meier estimates was assessed using the log-rank test. Median OS for prognostic groups according to MSKCC and IDC criteria, respectively, was 39.5 months (95 % confidence interval [CI]: 23.9-55.2) versus 44.3 months (95 % CI: 31.6-56.9) for favourable-risk patients (no adverse factors), 28.5 months (95 % CI: 20.1-36.8) versus 24.8 months (95 % CI: 19.8-29.8) for intermediate-risk patients (1-2 adverse factors), and 10.6 months (95 % CI: 6.3-14.8) versus 9.3 months (95 % CI: 5.1-13.5) for poor-risk patients (a parts per thousand yen3 adverse factors). The majority of MSKCC poor-risk patients (54.1 %, n = 72) were reclassified as intermediate-risk using IDC criteria, and 20.2 % (n = 61) of MSKCC intermediate-risk patients were reclassified to the IDC favourable-risk group. Both prognostic models were validated in the present cohort. Use of the IDC model resulted in an upward shift in prognostic assessment compared to the MSKCC model.
VytisknoutZobrazeno: 26. 10. 2020 09:12